Prostate Cancer News and Research

Latest Prostate Cancer News and Research

Advaxis added to Mentor Capital Cancer Immunotherapy Index

Mentor Capital, Inc. reports that Advaxis, Inc. has been added as the newest member of the Mentor Capital Cancer Immunotherapy Index.

16 Feb 2011

New review: Multiple interventions might enable work-related outcomes among cancer survivors

For cancer survivors who wish to return to work after treatment, a new evidence review suggests that therapies focusing on a wide range of health interventions might best enable them to do so.

16 Feb 2011

Genetic proof for anti-cancer properties of antioxidants and autophagy inhibitors

Researchers from Jefferson's Kimmel Cancer Center have genetic evidence suggesting the antioxidant drugs currently used to treat lung disease, malaria and even the common cold can also help prevent and treat cancers because they fight against mitochondrial oxidative stress-a culprit in driving tumor growth.

16 Feb 2011

RPCI offers first FDA-approved cancer treatment vaccine

The nation's first FDA-approved cancer treatment vaccine, Provenge, is being offered for the first time in Western New York at Roswell Park Cancer Institute.

15 Feb 2011

Men going bald at young age more likely to develop prostate cancer in later life

Men who start to lose hair at the age of 20 are more likely to develop prostate cancer in later life and might benefit from screening for the disease, according to a new study published online in the cancer journal, Annals of Oncology today.

15 Feb 2011

Unmet need for medical help to address sexual issues in breast, gynecologic cancer survivors

Many women who survive breast and gynecologic cancers want medical help for their sexual issues, but most do not get it. A survey of hundreds of cancer survivors, published online in the journal Cancer, confirms that more than forty percent want medical attention for their sexual health needs.

15 Feb 2011

Vitamin D levels not linked to prostate cancer development

Vitamin D levels do not affect men's chances of developing prostate cancer, according to new research published in the journal Cancer Causes and Control.

14 Feb 2011

Sequencing of whole prostate cancer genomes - an historic development

Today's announcement regarding the sequencing of whole prostate cancer genomes is an historic development in the fight against prostate cancer. The ability to sequence whole genomes will spare some patients from unnecessary treatments and side effects while eliminating an estimated $1.5 billion that is spent each year on overtreatment. The complete research findings will be published in the February 10 issue of Nature.

14 Feb 2011

Genetic map for prostate cancer

Researchers have managed to uncover the whole genetic sequence in prostate cancer. This complete map, hope researchers, will eventually lead to the development of more targeted drugs and a better understanding of which prostate cancers are likely to spread, one of the biggest challenges for physicians and patients.

13 Feb 2011

Genes for prostate cancer mapped for the first time

A genetic blue print that uncovers many of the mutations and genetic damage that drives prostate cancer and could lead to new treatments and better diagnosis has been found. This would mean earlier detection and new breeds of drugs to reverse the damage. Also each patient could have his own “cancer chart” made so that his treatment is personalized. The study, conducted by researchers from the Broad Institute, Dana-Farber Cancer Institute and Weill Cornell Medical College, appears in the Feb. 10 issue of Nature.

13 Feb 2011

Genta initiates new Phase 2 clinical trial of tesetaxel in patients with advanced prostate cancer

Genta Incorporated today announced that the Company has initiated a new Phase 2 clinical trial of tesetaxel in patients with advanced prostate cancer. Tesetaxel, the leading oral taxane in clinical development, will be evaluated for its use as both first- and second-line chemotherapy.

10 Feb 2011

Full genetic blueprint of multiple prostate tumors laid bare

For the first time, researchers have laid bare the full genetic blueprint of multiple prostate tumors, uncovering alterations that have never before been detected and offering a deep view of the genetic missteps that underlie the disease. The study, made possible by key advances in whole genome sequencing and analysis, points to several new prostate cancer genes and a critical category of genomic changes as important drivers of prostate cancer growth.

10 Feb 2011

Myriad Genetics' 46-gene PROLARIS molecular diagnostic test predicts prostate cancer outcome

Myriad Genetics, Inc. announced today that a study published in Lancet Oncology shows the Company's 46-gene PROLARIS™ molecular diagnostic test significantly predicts prostate cancer outcome.

10 Feb 2011

Everolimus phase III study shows improved progression-free survival in patients with pNET

In an international Phase III randomized study, everolimus, an inhibitor of the mammalian target of rapamycin, has shown to dramatically improve progression-free survival for patients with advanced pancreatic neuroendocrine tumors, according to researchers from The University of Texas MD Anderson Cancer Center.

9 Feb 2011

PBNC technology may help detect cardiac disease, reduce diagnostic costs

Heart disease is a silent killer, but new microchip technology from Rice University is expected to advance the art of diagnosis.

9 Feb 2011

Men with high levels of CCP genes more likely to have fatal form of prostate cancer

A genetic pattern could predict how aggressive prostate cancer is before treatment, and whether the disease will come back in men who have already been treated, according to research published1 in the Lancet Oncology.

9 Feb 2011

Study finds dutasteride not cost-effective in prevention of prostate cancer in men at elevated risk

The popular drug dutasteride may not be a cost-effective way to prevent prostate cancer in men who are at elevated risk of developing the disease, according to findings by a UT Southwestern Medical Center researcher.

9 Feb 2011

CytRx's bafetinib helps reduce skeletal complications in cancer patients

CytRx Corporation, a biopharmaceutical company specializing in oncology, today announced that results from a series of preclinical studies show that bafetinib may be useful in preventing bone loss in cancer patients who are at high risk for this event.

8 Feb 2011

Study shows dogs can be trained to detect PCa by smelling urine

In the February 2011 issue of European Urology, Jean-Nicolas Cornu and colleagues reported the evaluation of the efficacy of prostate cancer detection by trained dogs on human urine samples.

8 Feb 2011

Executive wellness a legit corporate expense

At least once a year, executives from Ciena Corp. spend a day at Johns Hopkins University getting poked and prodded as they undergo tests for a barrage of potential ailments, from anemia to prostate cancer. They

8 Feb 2011

Prostate Cancer News and Research

Latest Prostate Cancer News and Research

Advaxis added to Mentor Capital Cancer Immunotherapy Index

New review: Multiple interventions might enable work-related outcomes among cancer survivors

Genetic proof for anti-cancer properties of antioxidants and autophagy inhibitors

RPCI offers first FDA-approved cancer treatment vaccine

Men going bald at young age more likely to develop prostate cancer in later life

Unmet need for medical help to address sexual issues in breast, gynecologic cancer survivors

Vitamin D levels not linked to prostate cancer development

Sequencing of whole prostate cancer genomes - an historic development

Genetic map for prostate cancer

Genes for prostate cancer mapped for the first time

Genta initiates new Phase 2 clinical trial of tesetaxel in patients with advanced prostate cancer

Full genetic blueprint of multiple prostate tumors laid bare

Myriad Genetics' 46-gene PROLARIS molecular diagnostic test predicts prostate cancer outcome

Everolimus phase III study shows improved progression-free survival in patients with pNET

PBNC technology may help detect cardiac disease, reduce diagnostic costs

Men with high levels of CCP genes more likely to have fatal form of prostate cancer

Study finds dutasteride not cost-effective in prevention of prostate cancer in men at elevated risk

CytRx's bafetinib helps reduce skeletal complications in cancer patients

Study shows dogs can be trained to detect PCa by smelling urine

Executive wellness a legit corporate expense

What to know about prostate cancer eBook

How microRNA is transforming science: From discovery to diagnostics

Advancing benzodiazepine detection

The Surgeon-Scientist Pioneering Regenerative Engineering

Prostate Cancer News and Research

Latest Prostate Cancer News and Research

What to know about prostate cancer eBook

How microRNA is transforming science: From discovery to diagnostics

Advancing benzodiazepine detection

The Surgeon-Scientist Pioneering Regenerative Engineering

Newsletters you may be interested in